Matrix Metalloproteinases as Targets for the Immune System during Experimental Arthritis

Journal of Immunology

Volumn 172, Issue 8, 2004, Pages 5063-5068

  Van Bilsen, Jolanda H M ^a,b   Wagenaar Hilbers, Josée P A ^a   Grosfeld Stulemeijer, Mayken C J T ^a   Van Der Cammen, Maarten J F ^a   Van Dijk, Mariska E A ^a   Van Eden, Willem ^a   Wauben, Marca H M ^a,c  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EPITOPE; MATRIX METALLOPROTEINASE; STROMELYSIN;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIGEN RECOGNITION; ARTHRITIS; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DISEASE MODEL; ENZYME ACTIVITY; IMMUNE SYSTEM; IMMUNOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; RAT; T LYMPHOCYTE;

EID: 1842423805     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.8.5063     Document Type: Article

References (45)

1. Breedveld, F. C. 1998. New insights in the pathogenesis of rheumatoid arthritis. J. Rheumatol. 53(Suppl.):3.
2. Panayi, G. S., S. Lanchbury, and G. H. Kingsley. 1992. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum. 35:729.
3. Brocke, S., A. Gaur, C. Piercy, A. Gautam. K. Gijbels, C. G. Fathman, and L. Steinman. 1993. Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature 365:642.
4. Cole, B. C., and M. M. Griffiths. 1993. Triggering and exacerbation of autoimmune arthritis by the Mycoplasma arthritidis superantigen MAM. Arthritis Rheum. 36:994.
5. Röcken, M., J. F. Urban, and E. M. Shevach. 1992. Infection breaks T-cell tolerance. Nature 359:79.
6. Oldstone, M. B. 1998. Molecular mimicry and immune-mediated diseases. FASEB J. 12:1255.
7. van Eden, W., E. J. M. Hogervorst, E. J. Hensen, R. van der Zee, J. D. A. van Embden, and I. R. Cohen. 1989. A cartilage mimicking T-cell epitope on a 65 kD mycobacterial heat-shock protein: adjuvant arthritis as a model for human rheumatoid arthritis. Curr. Top. Microbiol. Immunol. 145:27.
8. Holoshitz, J., Y. Naparstek, A. Ben-Nun, and I. R. Cohen. 1983. Lines of T lymphocytes induce or vaccinate against autoimmune arthritis. Science 219:56.
9. van Eden, W., J. E. R. Thole, R. van der Zee, A. Noordzij, J. D. A. van Embden, E. J. Hensen, and I. R. Cohen. 1988. Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. Nature 331:171.
10. van der Zee, R., W. van Eden, R. H. Meloen, A. Noordzij, and J. D. A. van Embden. 1989. Efficient mapping and characterization of a T cell epitope by the simultaneous synthesis of multiple peptides. Eur. J. Immunol. 19:43.
11. van Eden, W., J. Holoshitz, Z. Nevo, A. Frenkel, A. Klajman, and I. R. Cohen. 1985. Arthritis induced by a T-lymphocyte clone that responds to Mycobacterium tuberculosis and to cartilage proteoglycans. Proc. Natl. Acad. Sci. USA 82:5117.
12. Van Bilsen, J. H., J. P. Wagenaar-Hilbers, E. P. Boot, W. van Eden, and M. H. Wauben. 2002. Searching for the cartilage-associated mimicry epitope in adjuvant arthritis. Autoimmunity 35:201.
13. van der Zee, R., S. M. Anderton, C. A. F. Buskens, E. Alonso de Velasco, and W. van Eden. 1994. Heat shock protein T-cell epitopes as immunogenic carriers in subunit vaccines. In Peptides 1994 (Proceedings of the Twenty-Third European Peptide Symposium). H. L. S. Maia, ed. ESCOM, Leiden, p. 841.
14. Wauben, M. H. M., C. J. P. Boog, R. van der Zee, I. Joosten, A. Schlief, and W. van Eden. 1992. Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone. J. Exp. Med. 176:667.
15. Joosten, I., M. H. M. Wauben, M. C. Holewijn, K. Reske, L. O. Pedersen, C. F. Roosenboom, E. J. Hensen, W. van Eden, and S. Buus. 1994. Direct binding of autoimmune disease related T cell epitopes to purified Lewis rat MHC class II molecules. Int. Immunol. 6:751.
16. Hilgers, L. A., and H. Snippe. 1992. DDA as an immunological adjuvant. Res. Immunol. 143:494.
17. van Tienhoven, E. A., P. J. Kooten, J. G. Veenstra, M. H. Hage, W. van Eden, and C. P. Broeren. 2000. Induction of experimental autoimmune arthritis by a public epitope of the T cell receptor variable a domain of an arthritogenic T cell clone. Eur. J. Immunol. 30:2164.
18. Mia, M. Y., L. Zhang, A. Hossain, C. L. Zheng, O. Tokunaga, and O. Kohashi. 2000. Dimethyl dioctadecyl ammonium bromide (DDA)-induced arthritis in rats: a model of experimental arthritis. J. Autoimmun. 14:303.
19. Tarkowski, A., J. B. Sun, R. Holmdahl, J. Holmgren, and C. Czerkinsky. 1999. Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxoid conjugate vaccine. Arthritis Rheum. 42:1628.
20. McKown, K. M., L. D. Carbone, S. B. Kaplan, J. A. Aelion, K. M. Lohr, M. A. Cremer, J. Bustillo, M. Gonzalez, G. Kaeley, E. L. Steere, et al. 1999. Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum. 42:1204.
21. Verheijden, G. F., A. W. Rijnders, E. Bos, C. J. Coenen-de Roo, C. J. van Staveren, A. M. Miltenburg, J. H. Meijerink, D. Elewaut, F. de Keyser, E. Veys, and A. M. Boots. 1997. Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum. 40:1115.
22. De Graeff-Meeder, E. R., R. van der Zee, G. T. Rijkers, H. J. Schuurman, W. Kuis, J. W. Bijlsma, B. J. Zegers, and W. van Eden. 1991. Recognition of human 60 kD heat shock protein by mononuclear cells from patients with juvenile chronic arthritis. Lancet 337:1368.
23. van Eden, W., R. van der Zee, A. G. A. Paul, B. J. Prakken, U. Wendling, S. M. Anderton, and M. H. M. Wauben. 1998. Do heat shock proteins control the balance of T cell regulation in inflammatory diseases? Immunol. Today 19:303.
24. Absalameh, S., J. Mollenhauer, R. C. Casey, R. Al-Ward, and J. R. Kalden. 1999. A distinct 65 kDa chondrocyte membrane-specific autoantigen (CH65) triggers peripheral blood T-cell proliferation from rheumatoid arthritis patients. Arthritis Rheum. 42:S83.
25. Blass, S., F. Schumann, N. A. Hain, J. M. Engel, B. Stuhlmuller, and G. R. Burmester. 1999. p205 is a major target of autoreactive T cells in rheumatoid arthritis. Arthritis Rheum. 42:971.
26. Corrigall, V. M., M. D. Bodman-Smith, M. S. Fife, B. Canas, L. K. Myers, P. H. Wooley, C. Soh, N. A. Staines, D. J. Pappin, S. E. Berlo, et al. 2001. The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J. Immunol. 166:1492.
27. Boots, A. M., G. F. Verheijden, R. Schoningh, C. J. van Staveren, E. Bos, D. Elewaut, F. de Keyser, E. Veys, I. Joosten, and A. W. Rijnders. 1997. Selection of self-reactive peptides within human aggrecan by use of a HLA-DRB1*0401 peptide binding motif. J. Autoimmun. 10:569.
28. van der Burg, S. H., M. J. Visseren, R. Offringa, and C. J. Melief. 1997. Do epitopes derived from autoantigens display low affinity for MHC class 1? Immunol. Today 18:97.
29. Fairchild, P. J., and D. C. Wraith. 1996. Lowering the tone: mechanisms of immunodonimance among epitopes with low affinity for MHC. Immunol. Today 17:80.
30. ter Steege, J., M. Vianen, J. van Bilsen, J. Bijlsma, F. Lafeber, and M. Wauben. 2003. Identification of self-epitopes recognized by T cells in rheumatoid arthritis demonstrates matrix metalloproteinases as a novel T cell target. J. Rheumatol. 30:1147.
31. Yoshihara, Y., H. Nakamura, K. Obata, H. Yamada, T. Hayakawa, K. Fujikawa, and Y. Okada. 2000. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann. Rheum. Dis. 59:455.
32. Konttinen, Y. T., M. Ainola, H. Valleala, J. Ma, H. Ida, J. Mandelin, R. W. Kinne, S. Santavirta, T. Sorsa, C. Lopez-Otin, and M. Takagi. 1999. Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann. Rheum. Dis. 58:697.
33. Pap, T., Y. Shigeyama, S. Kuchen, J. K. Fernihough, B. Simmen, R. E. Gay, M. Billingham, and S. Gay. 2000, Differential expression pattern of membrane-type matrix metalloproteinases in rheumatoid arthritis. Arthritis Rheum. 43:1226.
34. Nakamura, H., Y. Fujii, E. Ohuchi, E. Yamamoto, and Y. Okada. 1998. Activation of the precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases. Eur. J. Biochem. 253:67.
35. Ahrens, D., A. E. Koch, R. M. Pope, M. Stein-Picarella, and M. J. Niedbala. 1996. Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. Arthritis Rheum. 39:1576.
36. Jovanovic, D. V., J. Martel-Pelletier, J. A. Di Battista, F. Mineau, F. C. Jolicoeur, M. Benderdour, and J. P. Pelletier. 2000. Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis. Arthritis Rheum. 43:1134.
37. Matsuno, H., K. Yudoh, Y. Watanabe, F. Nakazawa, H. Aono, and T. Kimura. 2001. Stromelysin-1 (MMP-3) in synovial fluid of patients with rheumatoid arthritis has potential to cleave membrane bound fas ligand. J. Rheum. 28:22.
38. Ito, A., A. Mukaiyama, Y. Itoh, H. Nagase, I. B. Thogersen, J. J. Enghild, Y. Sasaguri, and Y. Mori. 1996. Degradation of interleukin 1β by matrix metalloproteinases. J. Biol. Chem. 271:14657.
39. Schonbeck, U., F. Mach, and P. Libby. 1998. Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing. J. Immunol. 161:3340.
40. McQuibban, G. A., J. H. Gong, E. M. Tam, C. A. McCulloch, I. Clark-Lewis, and C. M. Overall. 2000. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289:1202.
41. Levi, E., R. Fridman, H. Q. Miao, Y. S. Ma, A. Yayon, and I. Vlodavsky. 1996. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor I. Proc. Natl. Acad. Sci. USA 93:7069.
42. McCawley, L. J., and L. M. Matrisian. 2001. Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol. 13:534.
43. Mauviel, A. 1993. Cytokine regulation of metalloproteinase gene expression. J. Cell. Biochem. 53:288.
44. MacNaul, K. L., N. Chartrain, M. Lark, M. J. Tocci, and N. I. Hutchinson. 1990. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts: synergistic effects of interleukin-1 and tumor necrosis factor-α on stromelysin expression. J. Biol. Chem. 265:17238.
45. van Bilsen, J. H., J. P. Wagenaar-Hilbers, M. J. van der Cammen, M. E. van Dijk, W. van Eden, and M. H. Wauben. 2002. Successful immunotherapy with matrix metalloproteinase-derived peptides in adjuvant arthritis depends on the timing of peptide administration. Arthritis Res. 4:R2.